{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"1035","value":"324"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"}],"units":"Participants"}],"description":"The duration of overall response is measured from the time measurement criteria are met for Complete Remission or Partial Response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented.","dispersionType":"Full Range","groups":[{"description":"Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.\n\nromidepsin: Given IV\n\nlenalidomide: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Romidepsin, Lenalidomide)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Assessed from start of therapy for up to 3 years","title":"Duration of Response, Defined Per Cheson Criteria","type":"SECONDARY","unitOfMeasure":"Days"}